Financial Performance - Praxis reported a net loss of $69.3 million for Q1 2025, compared to a net loss of $39.6 million in Q1 2024[12]. - Net loss for Q1 2025 was $69,296,000, compared to a net loss of $39,553,000 in Q1 2024, representing an increase in loss of approximately 75.3%[26]. - Net loss per share attributable to common stockholders increased from $2.84 in Q1 2024 to $3.29 in Q1 2025, a rise of about 15.8%[26]. - Accumulated deficit grew from $836,740,000 on December 31, 2024, to $906,036,000 on March 31, 2025, an increase of about 8.3%[24]. Research and Development - Research and development expenses increased to $60.8 million for Q1 2025, up from $27.0 million in Q1 2024, primarily due to increased expenses related to the Cerebrum™ platform[10]. - Research and development expenses increased to $60,806,000 in Q1 2025, up from $26,984,000 in Q1 2024, reflecting a rise of approximately 125.5%[26]. - Total operating expenses rose to $74,728,000 in Q1 2025, compared to $42,317,000 in Q1 2024, an increase of about 76.4%[26]. - Praxis plans to initiate pivotal studies for relutrigine and elsunersen by mid-2025, targeting developmental and epileptic encephalopathy[1]. Cash and Investments - Praxis reported cash and investments of $472 million as of March 31, 2025, maintaining a runway into 2028[1]. - Cash and cash equivalents decreased by $49,805,000, from $215,372,000 to $165,567,000, representing a decrease of about 23.1%[24]. - Total assets decreased from $483,110,000 on December 31, 2024, to $478,736,000 on March 31, 2025, a decline of approximately 0.8%[24]. Collaboration Revenue - Praxis did not recognize any collaboration revenue in Q1 2025, a decrease from $0.4 million in Q1 2024, due to the completion of obligations under an agreement with UCB[9]. - Collaboration revenue dropped to $0 in Q1 2025, down from $431,000 in Q1 2024, indicating a significant decline[26]. Clinical Studies and Results - The registrational cohort of the EMBOLD study is on track for topline results no later than the first half of 2026[2]. - Topline results for vormatrigine from the RADIANT study are expected by mid-2025, with additional results from the POWER1 study anticipated in the second half of 2025[2]. - The EMPOWER registrational study has over 3,000 patients registered to date, supporting recruitment for the RADIANT and POWER1 studies[5]. - The Phase 1 food effect study for vormatrigine demonstrated that food intake does not significantly impact its absorption, enhancing dosing flexibility[3]. - The Essential3 study for ulixacaltamide is expected to complete topline readout in Q3 2025, despite an interim analysis recommending study stoppage for futility[5]. Other Income - Other income increased from $2,333,000 in Q1 2024 to $5,432,000 in Q1 2025, reflecting an increase of approximately 133.5%[26].

Corporate Update - Praxis Precision Medicines is on track for six major study readouts across four programs over the next 12 months, with pivotal studies for developmental and epileptic encephalopathy (DEE) programs set to begin in mid-2025 [1][2] - The company reported cash and investments of $472 million as of March 31, 2025, which is expected to fund operations into 2028 [1][6] Product Development - Vormatrigine is demonstrating a best-in-class safety profile, with new data showing no food effect and higher dosing tolerability [1][3] - The registrational cohort of the EMBOLD study is recruiting strongly, with topline results expected by the first half of 2026 [2][5] - The EMERALD study for relutrigine will be initiated in mid-2025, targeting a broader DEE patient population [2][5] - The EMBRAVE study with elsunersen is progressing well, with topline results expected in the first half of 2026 [2][5] Financial Performance - Research and development expenses increased to $60.8 million for Q1 2025, compared to $27.0 million in Q1 2024, primarily due to increased expenses related to the Cerebrum™ platform [8] - General and administrative expenses decreased to $13.9 million for Q1 2025, down from $15.3 million in Q1 2024 [9] - The net loss for Q1 2025 was $69.3 million, compared to a net loss of $39.6 million in Q1 2024 [10][21]

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and more prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [3] Upcoming Event - Praxis will host a virtual investor event on May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT, focusing on its clinical programs in developmental and epileptic encephalopathies (DEEs) [1][2] - The event will be led by the Praxis management team, and a replay will be available for 90 days on the company's website [2] Clinical Studies - The company is conducting several studies, including: - The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs [4] - The EMERALD study evaluating relutrigine for broader DEEs [4] - The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE [4]

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April: Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare Conference, ta ...

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences: Praxis management will be presenting a corporate overview at the 45th Annual TD Cowen Health Care Conference, taking place at t ...

Core Insights - The article emphasizes the author's expertise in healthcare and technology investments, particularly in biotech stocks, by analyzing clinical data and market dynamics [1] - The author utilizes financial theory and DCF modeling to identify key valuation drivers and make scenario-based forecasts [1] Group 1: Author's Background - The author has been writing for Seeking Alpha since 2017, focusing on healthcare and technology investments [1] - The author has a background as a Registered Nurse, which aids in the analysis of biotech stocks [1] - An MBA provides the author with a foundation in financial theory, allowing for a broader investment analysis [1] Group 2: Analytical Approach - The author evaluates clinical data, treatment guidelines, and market dynamics to analyze biotech stocks [1] - Key valuation drivers are identified through DCF modeling for scenario-based forecasts [1] - The author's thinking is influenced by literature such as "Superforecasting" and "Fooled by Randomness" [1]

Group 1 - Praxis Precision Medicines reported a quarterly loss of $2.94 per share, slightly better than the Zacks Consensus Estimate of a loss of $2.96, and an improvement from a loss of $2.97 per share a year ago, indicating an earnings surprise of 0.68% [1] - The company achieved revenues of $7.46 million for the quarter ended December 2024, significantly surpassing the Zacks Consensus Estimate by 1,467.86%, compared to revenues of $0.52 million in the same quarter last year [2] - The stock has underperformed, losing about 15.5% since the beginning of the year, while the S&P 500 has declined by only 0.3% [3] Group 2 - The earnings outlook for Praxis Precision Medicines is mixed, with the current consensus EPS estimate for the coming quarter at -$2.80 on $0.5 million in revenues, and -$12.22 on $1.91 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8] - Atara Biotherapeutics, a peer in the same industry, is expected to report a quarterly loss of $3.82 per share, reflecting a year-over-year change of +72.7%, with revenues projected to be $13.1 million, up 208.2% from the previous year [9]

Financial Performance - The company reported net losses of $182.8 million and $123.3 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $836.7 million as of December 31, 2024[487]. - The net loss for 2024 was $182.819 million, compared to a net loss of $123.277 million in 2023, indicating a year-over-year increase in losses of approximately 48%[577]. - The net loss for the quarter ending September 30, 2024, was $58,679, compared to a net loss of $51,910 for the quarter ending June 30, 2024, indicating a sequential increase in losses of about 13.5%[584]. - The company reported a net loss of $32,677 for the quarter ending June 30, 2024, which was an improvement compared to a net loss of $39,553 for the quarter ending March 31, 2024[584]. - The balance of accumulated deficit increased to $(836,740) as of December 31, 2024, from $(778,061) at September 30, 2024, reflecting a worsening of approximately 7.5%[584]. Revenue Generation - The company has not generated any revenue from product sales since inception and does not expect to do so for several years, but recognized $8.6 million and $2.4 million of collaboration revenue from a partnership with UCB Biopharma SRL during the years ended December 31, 2024 and 2023, respectively[502]. - Collaboration revenue rose by $6.1 million to $8.6 million in 2024, primarily due to an option exercise fee from UCB[519]. - The Company recognized $8.6 million in collaboration revenue for the year ended December 31, 2024, compared to $2.4 million for the year ended December 31, 2023[680]. - Upon UCB exercising its option in December 2024, the Company recognized a $6.0 million option exercise fee as collaboration revenue[679]. Cash and Funding - The company has cash, cash equivalents, and marketable securities of $469.5 million as of December 31, 2024, which are expected to fund operations into 2028[498]. - The company raised $1.1 billion in aggregate cash proceeds from various stock offerings since inception[523]. - A public offering in April 2024 generated approximately $216.0 million in net proceeds from the sale of common stock[495]. - The company completed a public offering in January 2024, generating approximately $161.6 million in net proceeds after expenses[527]. - The company expects its cash and marketable securities will be sufficient to fund operations for at least one year from the issuance of the financial statements[598]. Research and Development - Total research and development expenses increased by $65.6 million to $152.4 million in 2024, up from $86.8 million in 2023[507]. - The company plans to continue advancing its product candidates and expanding its research and development activities, requiring substantial additional funding[488]. - The company anticipates that research and development expenses will be maintained or increase as product candidates advance through development[507]. - The company is focused on developing therapies for central nervous system disorders through its two proprietary platforms, Cerebrum™ and Solidus™, with multiple clinical-stage product candidates[592]. Stock and Equity - A reverse stock split of 1-for-15 was executed on November 28, 2023, affecting the company's common stock[499]. - The company's additional paid-in capital rose to $1.282 billion in 2024, up from $723.577 million in 2023, reflecting an increase of about 77%[575]. - The weighted average common shares outstanding increased to 17,906,794 in 2024 from 6,594,316 in 2023, indicating a growth of approximately 172%[577]. - The total number of shares outstanding increased from 17,755,506 on June 30, 2024, to 19,422,358 by December 31, 2024, representing an increase of approximately 9.4%[584]. Operating Expenses - Total operating expenses rose to $208.718 million in 2024, compared to $128.820 million in 2023, reflecting an increase of about 62%[577]. - General and administrative expenses increased by $14.3 million to $56.3 million in 2024, up from $42.1 million in 2023[518]. - The Cerebrum™ platform saw a $61.9 million increase in expenses, mainly driven by a $49.8 million rise in spending for the ulixacaltamide program[520]. - The company incurred stock-based compensation expenses of $41.4 million in 2024, up from $24.9 million in 2023, reflecting a 66% increase[590]. Clinical Trials and Studies - The Phase 3 Essential3 clinical trials for ulixacaltamide are ongoing, with topline results expected in the third quarter of 2025[483]. - The company announced positive results from the Photo-Paroxysmal Response study for vormatrigine in Q1 2024 and has initiated multiple studies to gather further data[484]. - The EMBOLD study for relutrigine has shown positive topline results from the first cohort, with the second cohort currently enrolling and results expected in the first half of 2026[484]. Tax and Deferred Assets - The company has U.S. federal and state net operating loss carryforwards that may offset future taxable income, beginning to expire in 2035[516]. - The company has not recorded any U.S. federal or state income tax benefits for net losses incurred since inception[516]. - The Company assesses the likelihood of recovering deferred tax assets based on future taxable income and establishes a valuation allowance if necessary[647]. Collaboration Agreements - As of December 31, 2024, the Company had an option and license agreement with UCB Biopharma SRL, entered into in December 2022, and a collaboration and license agreement with Tenacia Biotechnology, entered into in January 2024[635]. - The Company entered into a Collaboration Agreement with UCB in December 2022, receiving a $5.0 million upfront payment for research services[677]. - The Collaboration Agreement allows UCB to in-license global development and commercialization rights, with potential milestone payments totaling up to $98.5 million and tiered royalties on net sales[677].

Clinical Development and Trials - Praxis anticipates four pivotal readouts in 2025, with three late-stage assets having blockbuster potential and four commercial assets expected by 2028[1][2]. - The Essential3 program for ulixacaltamide in essential tremor is on track for an interim analysis in Q1 2025, with an NDA filing expected in 2025[1][4]. - Enrollment in the EMBOLD study for relutrigine cohort 2 is progressing, targeting an NDA filing in 2026[1][3]. - The RADIANT study for vormatrigine is expected to provide topline results in the first half of 2025, with the POWER1 study results anticipated by the end of 2025[1][3]. - Praxis plans to re-initiate a study of ulixacaltamide in Parkinson's disease following positive results from the Essential3 program[5]. - Praxis is currently focused on the expected timing of clinical trials and regulatory submissions for its programs[18]. Financial Position - Praxis has approximately $470 million in cash and investments at the end of 2024, supporting operations into 2028[1]. Study Results and Patient Engagement - The EMBOLD study for relutrigine showed a 46% placebo-adjusted reduction in monthly motor seizures over 16 weeks, with 77% reduction in ongoing open-label extension[7][11]. - Over 100,000 patients have expressed interest in participating in the Essential3 program since recruitment began in November 2023[4]. - The EMPOWER observational study has enrolled over 2,000 patients to characterize seizure burden, with early results shared at the 2024 American Epilepsy Society Annual Meeting[7]. Licensing and Collaborations - UCB has licensed the KCNT1 small molecule candidate for global development, with potential milestone payments totaling up to approximately $100 million[8]. Forward-Looking Statements - The company emphasizes that its forward-looking statements are based on information currently known and should not be solely relied upon[18]. - Praxis has no obligation to publicly update or revise any forward-looking statements made[18].

Core Insights - Praxis Precision Medicines, Inc. announced an interim analysis outcome for Study 1 of the Essential3 program, recommending the study be stopped for futility due to unlikely success in meeting primary efficacy endpoints [2] - Despite the interim analysis, the company will continue both Study 1 and Study 2, with topline results expected in Q3 2025, and will decide on NDA submission based on final results [3] - The company remains focused on other development programs, including upcoming topline results from studies on focal onset seizures and generalized epilepsy, and plans to initiate a registrational study for relutrigine by mid-2025 [4] Study Updates - The Independent Data Monitoring Committee (IDMC) advised Praxis to stop Study 1 for futility, suggesting alternative analysis methods for the final dataset [2] - Praxis will continue with both Study 1 and Study 2, expecting topline results in Q3 2025 [3] Financial Overview - As of December 31, 2024, Praxis reported $469.5 million in cash, cash equivalents, and marketable securities, a significant increase from $81.3 million in 2023, primarily due to public offerings [9] - The company recognized collaboration revenue of $7.5 million for Q4 2024 and $8.6 million for the full year, related to an agreement with UCB [10] - Research and development expenses rose to $56.3 million in Q4 2024 from $18.4 million in Q4 2023, totaling $152.4 million for the year, driven by increased costs associated with the Cerebrum™ platform [11] Operational Highlights - Praxis is advancing multiple programs, including the RADIANT and POWER1 studies for focal onset seizures and generalized epilepsy, with topline results expected in 2025 [4][6] - The company has received Rare Pediatric Disease Designation for relutrigine for Dravet Syndrome, marking its third such designation [6] - The EMBOLD study is currently enrolling patients, with topline results anticipated in the first half of 2026 [6] Shareholder Information - As of December 31, 2024, Praxis had 19.4 million shares of common stock outstanding [15]